Haitao LYU, Dr

FRSC (英國皇家化學會會士), FRSB(英國皇家生物學會會士), Principal Investigator (課題組長) in State Key Laboratory of Environmental and Biological Analysis (環境與生物分析國家重點實驗室), Member of European Academy of Sciences and Arts (歐洲科學與人文學院院士), Visiting Professor (客座教授), Haihe Laboratory of Modern Chinese Medicine (現代中醫藥海河實驗室), Deputy Director (副主任), Guangzhou-Hong Kong-Macau Universities Joint Laboratory of Interventional Medicine (介入醫學粵港澳高校聯合實驗室), Principal Investigator (課題組長), National Lab of Diseases and Omics (疾病與組學全國重點實驗室)

  • 7 Baptist University Road, 4/F, Jockey Club School of Chinese Medicine Building, Hong Kong Baptist University

    Kowloon Tong

    Hong Kong

Accepting PhD Students

PhD projects

Functional Metabolomics Innovates Therapeutic Discovery of Pancreatic Cancer, IBD Diagnosis and Therapeutics, Drug Resistance

20102023

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Chinese Name

吕海涛

Biography

HAITAO LYU (LU) PH.D., MEASA, FRSC, FRSB

Associate Professor with Tenure, School of Chinese Medicine Hong Kong Baptist University, Hong Kong, China

Research Professor, HKBU Institute of Research and Continuing Education (IRACE)

Deputy Director, Guangzhou-Hong Kong-Macau Universities Joint Laboratory of Interventional Medicine

Principal Investigator, State Key Lab of Environmental and Biological Analysis (HKBU), National Lab of Diseases and Omics (SJTU)

Adjunct Professorship/PhD Supervisor, Macau University of Science and Technology (2020- )

Visiting Professorship, Haihe Laboratory of Modern Chinese Medicine (2024- )

Elected Member of European Academy of Sciences and Arts (2024)

Fellow of The Royal Society of Chemistry in UK (2021)

Fellow of The Royal Society of Biology in UK (2021)

Fellow of The Linnean Society of London in UK (2022)

Section Editor, Pharmacological Research (Q1, TOP) (Since 2020- )

Faculty Member, H1 Expert/Faculty Opinions (Faculty 1000 Prime) (2021)

Scientific Advisory Expert, Danaher (World Top 500 Companies) Life Sciences China (2022)

Dr. Haitao Lyu is an Associate Professor (tenured) at the School of Chinese Medicine, Hong Kong Baptist University. He also holds the position of Principal Investigator (PI) at the State Key Laboratory of Environmental and Biological Analysis (HKBU) and at the National Laboratory of Diseases and Omics. Dr. Lyu is the Deputy Director, Guangzhou-Hong Kong-Macau Universities Joint Laboratory of Interventional Medicine. Dr. Lyu is a research professor at the Hong Kong Baptist University Shenzhen Research Institute, an elected member of The European Academy of Sciences and Arts and a Fellow of the Royal Society of Chemistry (FRSC) and the Royal Society of Biology (FRSB). He is recognized as a Faculty Opinions (F1000 Prime) expert, and a visiting professorship in Haihe Laboratory of Modern Chinese Medicine (Tianjin, China). In addition, he is the Chief Expert at the Shanghai Academy of Science and Technology Expert Workstation. Previously, Dr. Lyu held the position of principal investigator (tenured) and PhD supervisor at the Institute of Systems Biomedicine at Shanghai Jiao Tong University. He also served as a principal investigator, PhD supervisor, and assistant dean at the Innovative Drug Research Center of the School of Pharmacy at Chongqing University. Earlier in his career, he worked as a postdoctoral research fellow at the Albert Einstein College of Medicine, the Washington University School of Medicine, and the Massachusetts Institute of Technology (SMART Center). Dr. Lyu's primary research focus lies in the application of cross-disciplinary sciences in life and health, driving the advancement of next-generation functional metabolomics research (STORM and STORM+). He has successfully led more than 15 projects, including the National Key R&D Program and the National Natural Science Foundation of China. His contributions to the field are evidenced by the publication of 60 SCI-indexed papers in authoritative journals within related fields, with 4 highly cited papers in the Essential Science Indicators (ESI). Dr. Lyu has co-edited one English book published by Wiley and one book on traditional Chinese medicine. Apart from his academic achievements, Dr. Lyu holds various positions of responsibility. He serves as the Deputy Secretary-General of the Metabolomics Committee of the Chinese Biophysical Society, The Vice Chairman of The Fangjiomics Speciality Committee of Chinese Pharmaceutical Association, the Deputy Secretary-General of the Network Pharmacology Committee of the Chinese Pharmacological Society, and The Vice Chairman of the Drug Metabolism Committee of the Guangdong Pharmacological Society. Furthermore, he actively contributes to the scientific community as an editor for Pharmacological Research (Section), Associate Editor for Royal Society Open Science, former Associate Editor for Phytomedicine, and an editorial board member for Proteomics. His expertise is also sought after as an expert reviewer for the National Natural Science Foundation of China and the Hong Kong Health and Medical Research Fund. Dr. Lyu's outstanding contributions have been recognized through several prestigious awards, including the 2021 Agilent Technologies Global Competitive ACT-UR Award, the 2022 Faculty Opinions Member of The Year Award, the 2013 QUT Vice Chancellor Research Fellowship, the 2022 APSB Outstanding Young Editorial Board Member Award, 2023 The Outstanding Editorial Board Member Award (Chinese Medicine Journal), 2023 The Outstanding Editorial Board Member Award (Acupunture and Herbal Medicine).

    吕海涛博士,香港浸会大学中医药学院副教授(终身)/博士生导师/PI,香港浸会大学深圳研究院研究员,环境与生物分析国家重点实验室PI,疾病与组学全国重点实验室(上海交大)PI,欧洲科学与人文学院院士(MEASA),英国皇家化学会会士(FRSC), 英国皇家生物学会会士(FRSB), 介入医学粤港澳高校联合实验室副主任,上海交通大学系统生物医学研究院客座研究员,上海院士专家工作站(专家级)首席专家,Faculty Opinions (F1000)特聘专家, 澳门科技大学兼职教授/博导, 现代中医药海河实验室客座教授。曾任上海交通大学系统生物医学研究院长聘教授,重庆大学药学院百人计划研究员/助理院长,美国华盛顿大学/爱因斯坦医学院/麻省理工学院博士后研究员。主要研究方向为生命健康交叉科学应用驱动的下一代功能代谢组学研究。主持国家重点研发计划课题等15项课题;权威杂志发表SCI检索论文60篇,ESI高被引4篇,共同主编中英文专业书籍各一部;国内外高水平学术会议和著名大学邀请报告50余场次。兼任中国生物物理学会代谢组学分会副秘书长、中国药理学会网络药理学专委会副秘书长和广东药理学会药物代谢专委会副主任委员等;任Pharmacological Research-Section主编,Royal Society Open Science副主编,Chinese Medicine编辑部副主任,ProteomicsActa Pharmaceutica Sinica B 编委和青年编委等;2021年度安捷伦科技全球竞争性ACT-UR Award获得者;2022年度APSB优秀青年编委奖获得者;2022年度Faculty Opinions Member of The Year Award获得者;2023年度Chinese Medicine杰出年度编委奖,QUT Vice Chancellor Research Fellowship (2013-2016), 2012 MIT-SMART Research Fellowship (2016)等,中国教育部科技成果奖等。国家自然基金会,澳大利亚NHMRC基金会, 中国香港HMRF基金会,国家重点研发计划和国家科技部重大人才计划评审专家。

    呂海濤博士,香港浸會大學中醫藥學院副教授(終身)/博士生導師/PI,香港浸會大學深圳研究院研究員,環境與生物分析國家重點實驗室PI,疾病與組學全國重點實驗室(上海交大)PI,歐洲科學與人文學院院士(MEASA),英國皇家化學會會士(FRSC), 英國皇家生物學會會士(FRSB),介入醫學粵港澳高校聯合實驗室副主任,上海交通大學系統生物醫學研究院客座研究員,上海院士專家工作站(專家級)首席專家,Faculty Opinions (F1000)特聘專家, 澳門科技大學兼職教授/博導, 現代中醫藥海河實驗室客座教授。曾任上海交通大學系統生物醫學研究院長聘教授,重慶大學藥學院百人計劃研究員/助理院長,美國華盛頓大學/愛因斯坦醫學院/麻省理工學院博士後研究員。主要研究方向為生命健康交叉科學應用驅動的下一代功能代謝組學研究。主持國家重點研發計劃課題等15項課題;權威雜誌發表SCI檢索論文60篇,ESI高被引4篇,共同主編中英文專業書籍各一部;國內外高水平學術會議和著名大學邀請報告50余場次。兼任中國生物物理學會代謝組學分會副秘書長、中國藥理學會網絡藥理學專委會副秘書長和廣東藥理學會藥物代謝專委會副主任委員等;任Pharmacological Research-Section主編,Royal Society Open Science副主編,Chinese Medicine編輯部副主任,Proteomics和Acta Pharmaceutica Sinica B 編委和青年編委等;2021年度安捷倫科技全球競爭性ACT-UR Award獲得者;2022年度APSB優秀青年編委獎獲得者;2022年度Faculty Opinions Member of The Year Award獲得者;2023年度Chinese Medicine傑出年度編委獎,QUT Vice Chancellor Research Fellowship (2013-2016), 2012 MIT-SMART Research Fellowship (2016)等,中國教育部科技成果獎等。國家自然基金會,澳大利亞NHMRC基金會, 中國香港HMRF基金會, 國家重點研發計劃和國家科技部重大人才計劃评審專家。

Research Interests

Dr. Haitao Lyu group has primarily focused on innovating methods and applying functional metabolomics in interdisciplinary life and health sciences. Specific Research Themes including, 1) Functional Metabolomics (STORM an STORM+).  2)Precision Oncology. 3. Small-Molecular Drug Discovery for Pancreatic Cancer, Hepatocellar Cancer, Rheumatoid Arthritis, and Ulcer Colitis, etc

    面向生命健康交叉科学领域挑战性关键科学问题,秉承变革分子科学理念,重点推动下一代功能代谢组学基础原创发现驱动现代中医药临床转化应用研究,推动肿瘤、关节炎和肠炎等复杂疾病的诊断试剂盒和中药源小分子创新药物研发。

    面向生命健康交叉科學領域挑戰性關鍵科學問題,秉承變革分子科學理念,重點推動下一代功能代謝組學基礎原創發現驅動現代中醫藥臨床轉化應用研究,推動腫瘤、關節炎和腸炎等復雜疾病的診斷試劑盒和中藥源小分子創新藥物研發。

Other Name(s)

Haitao Lu or Haitao Lv

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being
  • SDG 9 - Industry, Innovation, and Infrastructure
  • SDG 12 - Responsible Consumption and Production

Education/Academic qualification

Research, PhD, Pharmacognosy , Heilongjiang University of Traditional Chinese Medicine

1 Sept 20041 Jul 2009

Award Date: 1 Jul 2009

Research, Bachelor, Pharmacy in Chinese Medicine , Heilongjiang University of Traditional Chinese Medicine

1 Sept 20001 Jul 2004

Award Date: 1 Jul 2004

Keywords

  • QD Chemistry
  • RM Therapeutics. Pharmacology
  • RS Pharmacy and materia medica

Fingerprint

Dive into the research topics where Haitao LYU is active. Topic labels come from the works of this scholar.
  • 1 Similar Scholars

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or